Literature DB >> 28649316

Discovery of Decamidine as a New and Potent PRMT1 Inhibitor.

Jing Zhang1, Kun Qian1, Chunli Yan2, Maomao He1, Brenson A Jassim1, Ivaylo Ivanov2, Yujun George Zheng1.   

Abstract

Protein arginine methyltransferase 1 (PRMT1) is a key player for the dynamic regulation of arginine methylation. Its dysregulation and aberrant expression are implicated in various pathological conditions, and a plethora of evidence suggests that PRMT1 inhibition is of significant therapeutic value. Herein, we reported the modification of a series of diamidine compounds with varied lengths in the middle alkyl linker for PRMT1 inhibition. Decamidine (2j), which possesses the longest linker in the series, displayed 2- and 4- fold increase in PRMT1 inhibition (IC50 = 13 μM), as compared with furamdine and stilbamidine. The inhibitory activity toward PRMT1 was validated by secondary orthogonal assays. Docking studies showed that the increased activity is due to the extra interaction of the amidine group with the SAM binding pocket, which is absent when the linker is not long enough. These results provide structural insights into developing the amidine type of PRMT1 inhibitors.

Entities:  

Year:  2017        PMID: 28649316      PMCID: PMC5477784          DOI: 10.1039/C6MD00573J

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  21 in total

1.  Crystal structure of the conserved core of protein arginine methyltransferase PRMT3.

Authors:  X Zhang; L Zhou; X Cheng
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

2.  In vitro fungistatic activity of stilbamidine, propamidine, pentamidine and diethylstilbestrol.

Authors:  F C BOCOBO; A C CURTIS; E R HARRELL
Journal:  J Invest Dermatol       Date:  1953-09       Impact factor: 8.551

Review 3.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

4.  Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.

Authors:  Masanori Yoshimatsu; Gouji Toyokawa; Shinya Hayami; Motoko Unoki; Tatsuhiko Tsunoda; Helen I Field; John D Kelly; David E Neal; Yoshihiko Maehara; Bruce A J Ponder; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 5.  Protein arginine methyltransferases and cancer.

Authors:  Yanzhong Yang; Mark T Bedford
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

6.  Discovery and structure-activity analysis of 4-((5-nitropyrimidin-4-yl)amino)benzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors.

Authors:  Xu-Ri Yu; Yun Tang; Wen-Jing Wang; Sen Ji; Shuang Ma; Lei Zhong; Chun-Hui Zhang; Jiao Yang; Xiao-Ai Wu; Zheng-Yan Fu; Lin-Li Li; Sheng-Yong Yang
Journal:  Bioorg Med Chem Lett       Date:  2015-07-03       Impact factor: 2.823

Review 7.  HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.

Authors:  Sophia Rangwala; Chunlei Zhang; Madeleine Duvic
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

8.  Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation.

Authors:  Juxian Wang; Limin Chen; Sarmistha Halder Sinha; Zhongjie Liang; Huifang Chai; Sakthivel Muniyan; Yu-Wei Chou; Chao Yang; Leilei Yan; You Feng; Keqin Kathy Li; Ming-Fong Lin; Hualiang Jiang; Yujun George Zheng; Cheng Luo
Journal:  J Med Chem       Date:  2012-09-12       Impact factor: 7.446

9.  Novel symmetrical ureas as modulators of protein arginine methyl transferases.

Authors:  Noelia Fontán; Patricia García-Domínguez; Rosana Álvarez; Ángel R de Lera
Journal:  Bioorg Med Chem       Date:  2013-01-22       Impact factor: 3.641

Review 10.  Novel therapeutic agents for cutaneous T-Cell lymphoma.

Authors:  Salvia Jain; Jasmine Zain; Owen O'Connor
Journal:  J Hematol Oncol       Date:  2012-05-17       Impact factor: 17.388

View more
  7 in total

1.  Inhibition of Arginine Methylation Impairs Platelet Function.

Authors:  Alistair James Marsden; David R J Riley; Antonia Barry; Jawad S Khalil; Barbara-Ann Guinn; Neil T Kemp; Francisco Rivero; Pedro Beltran-Alvarez
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-09

2.  Pharmacophore-based screening of diamidine small molecule inhibitors for protein arginine methyltransferases.

Authors:  Kun Qian; Chunli Yan; Hairui Su; Tran Dang; Bo Zhou; Zhenyu Wang; Xinyang Zhao; Ivaylo Ivanov; Meng-Chiao Ho; Y George Zheng
Journal:  RSC Med Chem       Date:  2020-09-30

Review 3.  Computer-Aided Drug Design in Epigenetics.

Authors:  Wenchao Lu; Rukang Zhang; Hao Jiang; Huimin Zhang; Cheng Luo
Journal:  Front Chem       Date:  2018-03-12       Impact factor: 5.221

4.  Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling.

Authors:  Eunji Kim; Jiwon Jang; Jae Gwang Park; Kyung-Hee Kim; Keejung Yoon; Byong Chul Yoo; Jae Youl Cho
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

5.  Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

Authors:  Charlotte M J Wesseling; Cornelis J Slingerland; Shanice Veraar; Samantha Lok; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2021-11-12       Impact factor: 5.084

6.  PRMT1 is an important factor for medulloblastoma cell proliferation and survival.

Authors:  Xiao Gu; Miao He; Timofey Lebedev; Cheng-Han Lin; Zhong-Yan Hua; Y George Zheng; Zhi-Jie Li; Jer-Yen Yang; Xing-Guo Li
Journal:  Biochem Biophys Rep       Date:  2022-10-06

Review 7.  The Methylation Status of the Epigenome: Its Emerging Role in the Regulation of Tumor Angiogenesis and Tumor Growth, and Potential for Drug Targeting.

Authors:  Luciano Pirola; Oskar Ciesielski; Aneta Balcerczyk
Journal:  Cancers (Basel)       Date:  2018-08-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.